322 related articles for article (PubMed ID: 29934935)
1. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Ivy KS; Brent Ferrell P
Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
[TBL] [Abstract][Full Text] [Related]
2. Chronic immune response dysregulation in MDS pathogenesis.
Barreyro L; Chlon TM; Starczynowski DT
Blood; 2018 Oct; 132(15):1553-1560. PubMed ID: 30104218
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
4. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.
Trowbridge JJ; Starczynowski DT
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 34129017
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
[TBL] [Abstract][Full Text] [Related]
6. Deconstructing innate immune signaling in myelodysplastic syndromes.
Varney ME; Melgar K; Niederkorn M; Smith M; Barreyro L; Starczynowski DT
Exp Hematol; 2015 Aug; 43(8):587-598. PubMed ID: 26143580
[TBL] [Abstract][Full Text] [Related]
7. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
9. The inflammatory microenvironment in MDS.
Yang L; Qian Y; Eksioglu E; Epling-Burnette PK; Wei S
Cell Mol Life Sci; 2015 May; 72(10):1959-66. PubMed ID: 25662443
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
[TBL] [Abstract][Full Text] [Related]
11. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
12. Innate immune signaling in the myelodysplastic syndromes.
Starczynowski DT; Karsan A
Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
[TBL] [Abstract][Full Text] [Related]
13. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.
Fattizzo B; Giannotta JA; Barcellini W
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751628
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
16. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
17. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
Cull AH; Rauh MJ
J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
[TBL] [Abstract][Full Text] [Related]
18. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
19. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
20. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
